Orexo strengthens the Executive Management Group
Robin Wright joins from BioScience Managers Limited, a specialist healthcare fund manager and corporate finance boutique, where he held the position as Head of Corporate Advisory Services. Robin has extensive experience in providing financial and strategic advice and idea generation for life science companies. Göran Smedegård, previously responsible for Business & Commercial Development, leaves his position at Orexo but will continue to work as a consultant for the company.
Orexo has also made some additional changes to the Executive Management Group. Göran Tornling, Head of R&D, leaves Orexo and his responsibilities are divided into two areas, pre-clinical research and development and clinical and pharmaceutical development. Charlotte Edenius will be responsible for pre-clinical research and development and joins the executive management group. Thomas Lundqvist, member of the Executive Management, will be responsible for clinical and pharmaceutical development.
“We are delighted over the recruitment of Robin Wright. He has demonstrated success in over 130 transactions in over 40 countries. Robin is indeed a skilled principal negotiator with excellent marketing and execution skills. Robin has a perfect profile for us in our continued work to develop Orexo and find future partners. The strengthening of the Executive Management Group is another step in becoming a profitable pharma company. I would also like to thank Göran Tornling for his excellent contributions to Orexo and wish him all the best in his future endeavours”, says Torbjörn Bjerke, President and CEO, Orexo AB.
For more information, please contact:
Torbjörn Bjerke, President and CEO, Orexo AB
Tel: +46 (0)708-66 19 90
Claes Wenthzel, Executive Vice President & CFO, Orexo AB
Tel: +46 (0)18-780 88 44